Testicular cancer clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 10, 2006, Pages 1038-1058

  Motzer, Robert J ^a   Bolger, Graeme B ^a   Boston, Barry ^a   Carducci, Michael A ^a   Fishman, Mayer ^a   Hancock, Steven L ^a   Hauke, Ralph J ^a   Hudes, Gary R ^a   Jonasch, Eric ^a   Kantoff, Philip ^a   Kuzel, Timothy M ^a   Lange, Paul H ^a   Levine, Ellis G ^a   Logothetis, Chris ^a   Margolin, Kim A ^a   Pohar, Kamal S ^a   Redman, Bruce G ^a   Robertson, Cary N ^a   Samlowski, Wolfram E ^a   Sheinfeld, Joel ^a  

^a NONE

Author keywords

Alpha fetoprotein; Cisplatin; Germ cell tumors; Human chorionic gonadotropin; Lactate dehydrogenase; NCCN clinical practice guidelines; Nonseminoma; Seminoma; Testicular cancer

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; MESNA; PACLITAXEL; VINBLASTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CHORIOCARCINOMA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; EMBRYONAL CARCINOMA; FAMILY HISTORY; GERM CELL TUMOR; HUMAN; LUNG FIBROSIS; LYMPH NODE DISSECTION; NEUROMUSCULAR DISEASE; ORCHIECTOMY; PARAAORTIC LYMPH NODE; PHYSICAL EXAMINATION; RAYNAUD PHENOMENON; SEMINOMA; TERATOMA; TESTIS BIOPSY; TESTIS CANCER; YOLK SAC TUMOR;

EID: 33751585163     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0087     Document Type: Conference Paper

References (33)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Jones RH, Vasey PA. Part I: Testicular cancer - management of early disease. Lancet Oncol 2003;4:730-737.
3. Fossa SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population based study of 29,515 US men. J Natl Cancer Inst 2005;97:1056-1066.
4. Jones WG, Fossa SD, Mead OM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005;23:1200-1208.
5. Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet 2005;366:293-300.
6. Alomary I, Samant R, Gallant V. Treatment of stage I seminoma: a 15 year review. Urol Oncol 2006;24:180-183.
7. Gospodarowicz M, Sturgeon JF, Jewitt MA. Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. Semin Oncol 1998;25:160-173.
8. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001;19:1629-1640.
9. Loehrer PJ Sr, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995;13:470-476.
10. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993;11:598-606.
11. Kondagunta GV, Bacik J, Bajorin D, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 2005;23:9290-9294.
12. De Santis M, Becherer A, Bokemeyer C, et al. 2-18 fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22:1034-1039.
13. Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995;13:2255-2262.
14. Puc HS, Heelan R, Mazumdar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1998;14:454-460.
15. Mencel PJ, Motzer RJ, Mazumdar M, et al. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994;12:120-126.
16. Sheinfeld J, Herr H. Role of surgery in management of germ-cell tumors. Semin Oncol 1998;25:203-209.
17. Carver BS, Sheinfeld J. The current status of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ-cell tumors. Nat Clin Pract Urol 2005;2:330-35.
18. Davis BE, Herr HW, Fair WR, et al. The management of patients with nonseminomatous germ-cell tumors of the testis with serologic disease only after orchiectomy. J Urol 1994;152:111-114.
19. Culine S, Theodore C, Terrier-Lacombe MJ, Droz JP. Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. J Urol 1996;155:1296-1298.
20. Foster R, Bihrle R. Current status of retroperitoneal lymph node dissection and testicular cancer: when to operate. Cancer Control 2002;9:277-283.
21. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ-cell tumors. Classic Papers and Current Comments: Highlights of Genitourinary Cancer Research 1998b;2:455-459.
22. International Germ Cell Cancer Collaborative Group: international germ-cell consensus classification: a prognostic factor-based staging system for metastatic germ-cell cancers. J Clin Oncol 1997;15:594-603.
23. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435-1440.
24. Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide + cisplatin vs vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ-cell tumors. J Clin Oncol 1988;6:1231-1238.
25. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ-cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989;7:387-391.
26. Jones RH, Vasey PA. Part II: testicular cancer - management of advanced disease. Lancet Oncol 2003;4:738-747.
27. Toner GC, Motzer RJ. Poor prognosis germ-cell tumors: current status and future directions. Semin Oncol 1998;25:194-202.
28. Motzer RJ, Geller NL, Tan CC, et al. Salvage chemotherapy for patients with germ-cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer 1991;67:1305-1310.
29. McCaffrey JA, Mazumdar M, Bajorin DF, et al. Ifosfamide + cis-platin regimens as first-line salvage therapy in germ-cell tumors: response and survival [abstract]. Proc Am Soc Clin Oncol 1996;14:250.
30. Loehrer PJ, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ-cell tumor. J Clin Oncol 1998;16:2500-2504.
31. Motzer RJ, Bosl GJ. High-dose chemotherapy for resistant germ-cell tumors: recent advances and future directions. J Natl Cancer Inst 1992;84:1703-1709.
32. Beyer J, Kramer A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ-cell tumors: a multivariate analysis of prognostic factors. J Clin Oncol 1996;14:2638-2645.
33. Wood DP, Herr H, Motzer RJ, et al. Surgical resection of solitary metastases after chemotherapy in patients with non-seminomatous germ-cell tumors and elevated serum tumor markers. Cancer 1992;70:2354-2357.